Vir Biotechnology Management
Management criteria checks 3/4
Vir Biotechnology's CEO is Marianne De Backer, appointed in Apr 2023, has a tenure of 2.75 years. total yearly compensation is $9.26M, comprised of 9.9% salary and 90.1% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth $1.21M. The average tenure of the management team and the board of directors is 2.2 years and 8 years respectively.
Key information
Marianne De Backer
Chief executive officer
US$9.3m
Total compensation
| CEO salary percentage | 9.95% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.2yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Some Analysts Just Cut Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates
Nov 10
The Play On Vir Biotechnology
Sep 03Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 09Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
May 11
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams.Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology
Mar 04Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Jan 09Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Invest In Growth?
Jan 07Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Dec 13Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
Nov 05Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
Nov 04Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Sep 08Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results
Aug 03Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
Jul 17Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$500m |
| Jun 30 2025 | n/a | n/a | -US$550m |
| Mar 31 2025 | n/a | n/a | -US$578m |
| Dec 31 2024 | US$9m | US$921k | -US$522m |
| Sep 30 2024 | n/a | n/a | -US$533m |
| Jun 30 2024 | n/a | n/a | -US$483m |
| Mar 31 2024 | n/a | n/a | -US$539m |
| Dec 31 2023 | US$39m | US$675k | -US$615m |
Compensation vs Market: Marianne's total compensation ($USD9.26M) is above average for companies of similar size in the US market ($USD3.37M).
Compensation vs Earnings: Marianne's compensation has been consistent with company performance over the past year.
CEO
Marianne De Backer (56 yo)
Dr. Marianne De Backer, MSc, Ph. D. MBA, is a CEO & Director of Vir Biotechnology, Inc., since April 03, 2023. She served as Independent Director at Kronos Bio, Inc. from January 25, 2021 to June 2023.Dr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$9.26m | 0.12% $ 1.2m | |
| Executive VP & CFO | 1.3yrs | US$1.92m | no data | |
| Executive VP | 3.3yrs | US$1.67m | 0.056% $ 578.8k | |
| Executive VP & Chief Medical Officer | 1.6yrs | US$2.76m | 0.075% $ 774.2k | |
| Co-Founder & Scientific Advisor | 10yrs | no data | no data | |
| Co-Founder & Scientific Advisor | no data | no data | no data | |
| Senior VP | 2.9yrs | no data | 0.034% $ 345.0k | |
| Executive VP & Chief Technical Operations Officer | less than a year | no data | no data | |
| Executive VP & Chief Scientific Officer | 2.2yrs | no data | no data | |
| Senior Vice President of Corporate Communications | 1yr | no data | no data | |
| Senior Vice President of Human Resources | 2yrs | no data | no data | |
| SVP & Senior Research Fellow | 8.1yrs | no data | no data |
Experienced Management: VIR's management team is considered experienced (2.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$9.26m | 0.12% $ 1.2m | |
| Co-Founder & Scientific Advisor | no data | no data | no data | |
| Co-Founder & Scientific Advisor | no data | no data | no data | |
| Independent Director | 9.8yrs | US$263.08k | 0.44% $ 4.5m | |
| Independent Director | 9.3yrs | US$283.08k | 0.0057% $ 59.2k | |
| Independent Chairman | 9.1yrs | US$295.58k | 0.83% $ 8.6m | |
| Scientific Advisor | no data | no data | no data | |
| Director | 9yrs | US$269.33k | 2.72% $ 28.0m | |
| Scientific Advisor | 7yrs | US$23.92k | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 5.1yrs | US$279.47k | 0.017% $ 176.2k | |
| Independent Director | 6.3yrs | US$285.93k | 0.011% $ 108.2k |
Experienced Board: VIR's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/23 00:00 |
| End of Day Share Price | 2026/01/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vir Biotechnology, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |